Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Application of Transcriptomics for Establishing Potential Prognostic Markers of Response to Treatment of Ulcerative Colitis With Ustekinumab

NCT05896943 is registered in ClinicalTrials.gov with Evangelismos Hospital as lead sponsor.

NCT NCT05896943
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05896943 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Application of Transcriptomics for Establishing Potential Prognostic Markers of Response to Treatment of Ulcerative Colitis With Ustekinumab
Lead sponsor
Evangelismos Hospital
Phase
Observational
Overall status
Completed
Start date
April 1, 2022
Completion date
September 25, 2024
Enrollment
38 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ulcerative colitis